Biggest Insulin Maker May Build Diabetes Drug Plant in U.S.

Updated on

An operator inspects production at the Kalundborg Novo Nordisk A/S insulin production facility in Denmark. Source: Novo Nordisk A/S via Bloomberg

About 90 minutes from Copenhagen, at a site the size of 140 soccer fields, the world’s largest maker of insulin runs its only factory making active ingredients for diabetes therapies. Novo Nordisk A/S may soon change that with a new U.S. facility.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.